This relatively specific inhibition of CML cells and the enhanced IM sensitivity of K562 cells caused by GAS2 targeting made GAS2 an interesting therapeutic target for the disease. Here, GAS2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.